Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8433 | 0.81 | HSPB1 (0.52) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL27912110 | 0.79 | HSPB1 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| Ammonia Solution, Strong SCHEMBL27663814 | 0.79 | HSPB1 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL830158 | 0.79 | HSPB1 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL28049499 | 0.79 | HSPB1 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL13665383 | 0.79 | HSPB1 (0.55) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL28049513 | 0.79 | HSPB1 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL535259 | 0.79 | HSD17B10 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL28135398 | 0.79 | HSPB1 (0.50) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 | |
| SCHEMBL132166 | 0.78 | HSPB1 (0.48) | HSPB1ALDH1A1HSD17B10LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772105-B | Synthesis method of 4-nitroanisole | 厦门大学 | 2024-06-11 | — | — | CN | claimed |
| CN-118022724-A | Bimetallic Pd-Zr/CN catalyst, preparation thereof and application thereof in hydrogenation sulfur-resistant system | 浙江工业大学 | 2024-05-14 | — | — | CN | claimed |
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | claimed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | claimed |
| CN-119793522-A | Multilayer core-shell structure catalyst and preparation method and application thereof | 浙江工业大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-115772105-B | Synthesis method of 4-nitroanisole | 厦门大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118022724-A | Bimetallic Pd-Zr/CN catalyst, preparation thereof and application thereof in hydrogenation sulfur-resistant system | 浙江工业大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-117899873-A | Transition metal catalyst and preparation method and application thereof | 厦门大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903022-A | Application of zirconium hydroxide as catalyst in preparing sulfoxide and sulfone by selective catalytic oxidation of thioether | 兰州大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-117138798-A | Composite material of carbon-coated nickel-palladium alloy nano particles, and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-115073311-B | Efficient preparation of N, N ′ Synthesis method of-di (2-hydroxyethyl) aniline | 河南大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | disclosed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| US-6743373-B1 | REAGENT BASED ON ENANTIOPURE AMINO ACID IN WHICH AMINO GROUP CARRIES ACTIVATING GROUP TO FORM ACTIVE PRECURSOR OF ISOCYANATE GROUP AND CARBOXYL GROUP IS SUBSTITUTED; SEPARATION OF ENANTIOMERS HAVING FREE FUNCTIONAL GROUP | SOLVAY (SOCIETE ANONYME) (BE) | 2004-06-01 | — | — | US | disclosed |
| EP-1046627-B1 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (BE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1046627-A2 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (Société Anonyme) (BE) | 2000-10-25 | — | — | EP | disclosed |
| US-4287125-A | Preparation of benzenoid ethers and thioethers | RHONE-POULENC INDUSTRIES (FR) | 1981-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | DNPEP, DAO, ANPEP | HSPB1 4202/4885ALDH1A1 685/4885HSD17B10 1333/4885 |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | KLKB1, SERPINB1, KLK1 | HSPB1 3217/4885ALDH1A1 1091/4885HSD17B10 1322/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | HSPB1 3217/4885ALDH1A1 1091/4885HSD17B10 1322/4885 |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | HSPB1 3217/4885ALDH1A1 1091/4885HSD17B10 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.